PRESS RELEASE - STADA Arzneimittel AG
PRESS RELEASE - STADA Arzneimittel AG
PRESS RELEASE - STADA Arzneimittel AG
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>PRESS</strong> <strong>RELEASE</strong><br />
<strong>STADA</strong> wins Omeprazol dispute with Astra<br />
Bad Vilbel, 08.09.1999. The publicly-quoted Bad Vilbel-based<br />
08.09.1999<br />
<strong>STADA</strong> wins<br />
Omeprazol dispute<br />
pharmaceuticals company <strong>STADA</strong> <strong>Arzneimittel</strong> <strong>AG</strong> announces that it has<br />
won an important legal victory before the Munich District Court.<br />
The Swedish Astra Group had accused the German generics subsidiary<br />
<strong>STADA</strong>pharm GmbH of patent violations in relation to the product<br />
Omeprazol <strong>STADA</strong>. There was no contention, however, about the<br />
pharmaceutical quality of the <strong>STADA</strong> product. Omeprazol <strong>STADA</strong> is an<br />
inexpensive generic replacement for the world’s leading stomach treatment<br />
Antra, with which the Astra Group generates sales of several billion<br />
German marks. In recent years, internationally-operating pharmaceutical<br />
research groups have increasingly been using legal means to make<br />
accusations of patent violations. Their aim is to prevent and delay cheaper<br />
generic drugs being offered in individual national pharmaceutical markets.<br />
This is in order to protect their own highly-priced products from outside<br />
competition for as long as possible, even after the patent covering the<br />
active substance has expired. It was for this reason that in April of this year<br />
Astra took to court a number of respected German companies involved in<br />
the marketing of generic products. In the case of another Omeprazol<br />
supplier a few days ago, this strategy proved successful.<br />
1/2
Yesterday, however, the Munich District Court rejected the Astra Group’s<br />
petition that Omeprazol <strong>STADA</strong> too should be kept from the market.<br />
Omeprazol <strong>STADA</strong> is and will remain available in the market as an<br />
inexpensive alternative to the Astra product Antra.<br />
Following the positive ruling of the Munich District Court, <strong>STADA</strong> is<br />
confident that both a possible appeal as well as the still-pending<br />
proceedings in the main action will result in its favour. Prescribing doctors<br />
can thus rest assured that they will continue to be able to obtain a secure<br />
supply of Omeprazol <strong>STADA</strong> as well as all other <strong>STADA</strong> generic drugs for<br />
their patients.<br />
2/2
Change language